Anavex Life Sciences Welcomes Dr. Audrey Gabelle to Advisory Board
Today, Anavex Life Sciences Corp. (NASDAQ: AVXL) proudly announces the appointment of Professor Dr. Audrey Gabelle, MD, PhD, to its Scientific Advisory Board. Anavex, a forward-thinking biopharmaceutical company, passionately focuses on creating transformative treatments for debilitating conditions such as Alzheimer's disease, Parkinson's disease, schizophrenia, and various neurodegenerative disorders.
Professor Dr. Audrey Gabelle: A Leader in Neurology
Dr. Gabelle, a well-respected figure in the field of predictive, personalized medicine, excels in treating Alzheimer's disease and related disorders. With her strong academic background as a Professor of Neurology and extensive experience as a clinician and researcher, she brings invaluable expertise to the Anavex team.
Expertise and Contributions
Her work encompasses over a decade of innovation in clinical trials, during which she has been pivotal in managing a network of over 400 memory centers in France. With more than 200 peer-reviewed scientific publications, Dr. Gabelle excels in public-private partnerships and has participated in significant research projects across Europe and beyond.
Innovative Research on Neurodegenerative Diseases
Dr. Gabelle is not only a researcher but also a visionary leader in developing the NeuroCognition biobank. Established since 2007, this biobank houses over 35,000 samples, aiding in groundbreaking research on biomarkers related to Alzheimer’s disease. She has further contributed to international cohorts aimed at risk stratification and prevention strategies for neurodegenerative disorders.
Dr. Gabelle's Focus on Digital Health and AI
Recently, Dr. Gabelle has directed her attention towards incorporating real-world evidence (RWE) and digital health technologies into her research. Her training at prestigious institutions such as Columbia University and Harvard University has enabled her to lead projects focusing on the intersection of digital health and neuroscience, enhancing patient care through innovation.
Highlighting her passion for progress, Dr. Gabelle expressed her excitement regarding the potential of Anavex’s lead compound, blarcamesine. She notes, "There is a tremendous unmet medical need around the globe caused by Alzheimer’s disease. I look forward to collaborating on cutting-edge science and helping guide the development of new therapies that can make a meaningful impact on neurodegenerative disorders. A small molecule administered orally once daily, with demonstrated clinically meaningful improvement and good safety profile could be a game changer for patients. I am committed to leveraging my experience to support Anavex’s mission to improve lives through novel precision medicine like blarcamesine."
A Vision for the Future at Anavex
Christopher U Missling, PhD, President and CEO of Anavex, expressed a warm welcome to Dr. Gabelle, emphasizing that her extensive knowledge in Alzheimer’s disease and digital health will significantly benefit the company. He stated, "I look forward to her active contributions in advancing blarcamesine to patients diagnosed with Alzheimer’s disease." This partnership marks a promising step forward in the ongoing quest to develop effective therapies for challenging neurodegenerative conditions.
About Anavex Life Sciences Corp.
As a publicly traded biopharmaceutical company, Anavex Life Sciences Corp. (NASDAQ: AVXL) is at the forefront of developing groundbreaking therapeutics for neurodegenerative and neurodevelopmental disorders. Its lead therapeutic candidate, ANAVEX®2-73 (blarcamesine), has shown immense potential in clinical trials for Alzheimer’s disease and related conditions, with ongoing studies for its efficacy in Parkinson’s disease and Rett syndrome as well.
ANAVEX®2-73 is designed to restore cellular balance by targeting key receptors in the brain, and preclinical trials indicate its ability to halt or potentially reverse the manifestation of Alzheimer’s disease. The prospects of ANAVEX®3-71, which is being evaluated for similar indications, also highlight the company’s dedication to addressing the critical needs in the field of neurodegenerative research.
Frequently Asked Questions
What is the role of Dr. Audrey Gabelle at Anavex?
Dr. Gabelle has been appointed to the Scientific Advisory Board to bring her expertise in neurology and digital health to Anavex.
What are Anavex’s primary areas of focus?
Anavex focuses on developing innovative treatments for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
Why is blarcamesine significant for Alzheimer's treatment?
Blarcamesine is a promising drug candidate that has shown clinically meaningful improvements in Alzheimer’s patients, targeting key receptors to restore brain function.
How does Anavex conduct its research?
Anavex conducts rigorous clinical trials and collaborates with leading experts and institutions to ensure that its research is at the cutting edge of science.
How can I contact Anavex for more information?
For more information, you can reach out to Anavex Life Sciences Corp. via their toll-free number or email provided in their contact information.
